Abstract: A treatment regime for use in the treatment or prevention of dermatitis and inflammatory skin conditions, said regime comprising the administration of: a) between 50 mg and 3000 mg of a topical liquid or gel composition comprising between 1% w/w and 15% w/w cannabinoid, wherein the cannabinoid is dissolved in the liquid or gel composition.

Abstract: Topical pain relief compositions include a cannabinoid, terpenoid, and skin penetration system that includes dimethyl sulfoxide (DMSO) and at least one compatibilizer. The composition may be in the form of an emulsion that contains water and at least one fatty component. The composition can be used to reduce or eliminate pain by direct topical application to an affected part or region of the body. A method of treating pain may include direct topical application of the composition to a joint, ligament, muscle, tendon, or disk. The composition penetrates through the skin to provide localized pain relief where applied and provides a quantity of cannabinoid in the region of the pain instead of distributing the cannabinoid systemically and/or to the brain or central nervous system. The composition may be applied by rubbing or massaging at the treatment site and/or by a bandage, patch or other barrier layer.

Abstract: It is disclosed a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof: wherein R1 is a linear alkyl group of 3 or 5 carbon atoms, and R2 is: and a pharmaceutical composition comprising the same, for use in the treatment of a disease whose treatment benefits from inhibiting or reducing Notch1 expression levels in cells, and/or benefits from inhibiting or reducing Notch1 levels in cells, and/or benefits from inhibiting or reducing Notch1 signaling dependent proteins levels in cells. As a consequence, present invention also relates to said compound of formula (I), and to the pharmaceutical composition comprising the same, for use in suppressing cancer stem cells, as well as, for use in reducing solid tumor development, metastasis or chemo/radio-resistance, promoted by cancer stem cells.

Abstract: Disclosed are compositions containing chemical constituents from plants, uses of these compositions and methods for making them. In various embodiments, the present invention relates to an improved modes of administration of herbal remedies.

Abstract: The present invention relates to a dental topical anesthetic gel containing a full spectrum blend of active cannabinoids and at least one component including tetracaine, benzocaine, lidocaine, and butamben. Further, the dental topical gel may also contain a chemical penetration enhancer, at least one drug to enhance the effects of cannabinoids, at least one antibacterial agent and at least one antifungal agent. The forms and use of the dental topical anesthetic gel are also disclosed.

Abstract: Peritoneal therapeutic fluid comprising one or more of a biocompatibility enhancing agent (BCA) that is selected from the group consisting of a polyphenolic compound, a metabolite of a polyphenolic compound which is obtained by metabolization in the human or animal body, a salt or a glycoside of a polyphenolic compound.

Abstract: Described herein are transdermal formulations of phytocannabinoids and methods of using the same in the treatment of pain and/or inflammation.

Abstract: The present invention describes extracts of Polygonum cuspidatum and related compositions that are capable of photodynamic inactivation (PDI) of microorganisms such as bacteria, viruses, fungi, and protozoa, and capable of killing or inactivating cancer cells. The present invention further describes methods of using said Polygonum cuspidatum extracts and photodynamic inactivation (PDI) as a therapy for the treatment of microbial infection and as well as the use of Polygonum cuspidatum extract and related compositions as photodynamic therapy agents for the treatment of cancer.

Abstract: A pharmaceutical compound TG1 (2, 3, 5, 4?-tetrahydroxy-trans-stilbene) and a new use for treating colorectal cancer thereof are provided. The pharmaceutical composition of the present invention has the structure of formula shown as below. Each variable in formula I and treating method are detailed in the specification.

Abstract: A composition for promoting antioxidative activity includes an effective dose of Rhodiola extract, an alpha-Glycerophosphocholine (alpha-GPC), and a pharmaceutically acceptable vehicle or salt thereof. Based on animal experiments, the combination of rhodiola extract and alpha-Glycerophosphocholine provides high antioxidative activity.

Abstract: The present invention discloses a topical composition comprising terpene blend and cannabidiol (CBD) or a derivative thereof, useful for managing pain, the treatment or prevention of inflammatory skin disorders, and treatment methods thereof. The composition includes 2-pyrrolidone-5-carboxylic acid and a blend of antioxidants to optimize tissue health.

Abstract: A method for delivering therapeutics includes infusing a hydrogel with cannabis; and contacting the hydrogel infused with cannabis into a human which causes the controlled timed releasing of the cannabis with hydrophobic molecules to permeate through a lipid pathway.

Abstract: The present invention provides methods for producing cannabinoids and cannabinoid analogs as well as a system for producing these compounds. The inventive method is directed to contacting a compound according to Formula I or Formula II with a cannabinoid synthase. Also described is a system for producing cannabinoids and cannabinoid analogs by contacting a THCA synthase with a cannabinoid precursor and modifying at least one property of the reaction mixture to influence the quantity formed of a first cannabinoid relative to the quantity formed of a second cannabinoid.

Abstract: The instant disclosure relates to microemulsion compositions comprising polydatin, which are useful as cosmetic and/or pharmaceutical compositions for application to the skin and/or hair. The microemulsion compositions comprise: (a) polydatin; (b) optionally, niacinamide; (c) optionally, baicalin; (d) one or more oils; (e) water; and (f) one or more emulsifiers. Furthermore, the ratio of the total amount of the one or more emulsifiers to the total amount of the one or more oils is typically 1.7 to 2.5.

Abstract: A phonophoretic cannabidiol composition comprises an amount of cannabidiol, an amount of a glucose source, such as honey, an amount of aloe vera, and amounts of one or more of glucosamine, methylsulfonylmethane, and chondroitin. A transdermal delivery system for administration of a phonophoretic cannabidiol composition includes a phonophoretic cannabidiol composition, a laser generator comprising an emitter which generates and directs a laser beam to the treatment area, and an ultrasound generator comprising a transducer which generates and transmits a plurality of ultrasonic waves to the treatment area. A method for transdermal delivery of a phonophoretic cannabidiol composition includes selecting laser pretreatment parameters, directing a laser beam to the treatment area, applying an amount of a phonophoretic cannabidiol composition to a treatment area, selecting ultrasonic treatment parameters, and, transmitting a plurality of ultrasonic waves to the treatment area.

Abstract: Compositions and methods for preventing and treating Neisseria gonorrhoeae infection with AR-12 alone or in combination with antibiotics are provided.

Abstract: Disclosed are compounds which can act as a positive allosteric modulator for erythropoietin and erythropoietin receptor and have the activity in promoting erythropoiesis. Also disclosed are pharmaceutical compositions comprising said compounds and treatment methods utilizing said compounds.

Abstract: Disclosed are compositions containing chemical constituents from plants, uses of these compositions and methods for making them. In various embodiments, the present invention relates to an improved modes of administration of herbal remedies.

Abstract: A method for treating radiotherapy- or chemotherapy-induced cognitive or emotional impairment by topically administering a cannabinoid. Also provided is a method for treating a tumor by topically administering a cannabinoid together with radiotherapy and/or chemotherapy.

Abstract: Compositions and pharmaceutical compositions including a dendrimer-resveratrol complex and methods for making and using the compositions are described herein. Methods of treating cancer, cardiovascular disease, cardiac failure, diabetes, Alzheimer's disease, Parkinson's disease and other brain diseases, fatty liver disease, obesity, cataracts, osteoporosis, muscle wasting, sleep disorders, acoustic trauma, inflammatory disease, psoriasis, arthritis, colitis, aging, viral disease, reproductive disease, and skin conditions or disorders including administering a therapeutically effective amount of the compositions to a subject in need are also provided. The compositions may be topically applied to skin or mucous membranes.

Abstract: This invention is related to dermal matrices and production method thereof, having within its structure micro particles having antioxidant agents with synergistic effects, providing speedy repair of the dermal tissue, used in chronic wound treatments, basically comprising the steps of preparing the dermal matrix system (11), forming micro particles (12), combining the micro particles with the dermal matrix system.

Abstract: Use of UV-filters to stabilize resveratrol in topical cosmetic compositions and to improve the efficacy of topical cosmetic skin whitening compositions containing resveratrol as skin whitening agent.

Abstract: A method for screening an active agent intended for preventing or combating the cutaneous signs resulting from a non-pathological impairment of barrier function, which includes the selection of active agents that stimulate the expression of the ceramide transport protein CERT in cultured human keratinocytes.

Abstract: The invention relates to a medicament comprising at least one reducing alkyl-sugar monomer having a hydroxyl function which is substituted by an alkoxy radical at C2-C40, said medicament being preferably intended to regulate inflammatory mechanisms. The reducing sugar is preferably selected from the group containing rhamnose, fucose and glucose. The invention also relates to a cosmetic treatment method involving the topical application of a composition comprising at least one reducing alkyl-sugar monomer having a hydroxyl function which is substituted by an alkoxy radical at C2-C40.

Abstract: Pharmaceutical compositions including D-tagatose along with a stilbene or stilbenoid component, or a salt or derivative thereof. Methods of prophylaxis and therapy by administering to a mammal a pharmaceutically effective amount of D-tagatose, optionally in combination with a stilbene or stilbenoid component, or a salt or derivative thereof to prevent or treat atherosclerosis, the metabolic syndrome, obesity, or diabetes.

Abstract: Provided are methods of using curcuphenol compounds to increase expression of major histocompatibility complex class I (MHC-I) antigen in cells, particularly on the surface of diseased cells such as cancer cells, and thereby increase the immunogenicity of the cells. Also provided are pharmaceutical compositions that comprise curcuphenol compounds and methods of use thereof, for instance, to treat various cancers, alone or in combination with other therapies.

Abstract: The present invention relates to a granulate comprising granules made up of 40-99 wt. % of lactose particles and 1-60 wt. % of a binding component that holds together the lactose particles within the granules. Said granules have a mass weighted average diameter of 50-500 ?m and said binding component is a solid dispersion or a solid solution of 10-75 wt. % of a cannabinoid in 25-80 wt. % of a lipophilic matrix. The lipophilic matrix contains at least 80 wt. % sucrose fatty acid mono-ester, the fatty acid residue being selected from C8-C18 fatty acids. The aforementioned granulate can be processed into oral dosage units in the form of tablets for oral delivery. The invention further provides a method for the manufacture of the granulate.

Abstract: A dietary supplement is disclosed comprising lycopene and resveratrol in a range of ratio of lycopene:resveratrol from 1:10 to 10:1. Preferably, the ratio is 1:2 to 1:4. Lycopene is preferably of ?95% purity and resveratrol is of ?98% purity. Both lycopene and resveratrol may preferably comprise of nano-sized particles in crystal powder to optimize oral intake in the form of capsule or tablet. In small dosage, it should preferably include a minimum of 5 mg of lycopene and 10 mg of resveratrol. Various range of ratios of lycopene:resveratrol are provided for specific therapeutic purposes including 1:4 for symptomatic relief of arthritis, 1:2 for inhibiting melanoma or carcinoma malignancy, and 1:3 for inhibiting hyperlipoidemia. Generally, our dietary supplement composition may be used as an agent for anti-ageing, anti-oxidative, inhibiting cardiovascular diseases, relieving menopause symptoms and remission of post-operative cancer patients.

Abstract: Formulations and methods for weight loss and body contouring are disclosed. An illustrative formulation comprises human chorionic gonadotrophin (hCG) and resveratrol. An illustrative method for weight loss and body contouring comprises administering hCG and resveratrol sublingually.

Abstract: Disclosed is a novel sirtuin modulating composition comprising an orally bioavailable SIRT-1 enhancing compound 3,5-dimethoxy-3,4?-dihydroxystilbene represented by STR#I. Also disclosed is an anti-acne composition comprising 3,5-dimethoxy-3,4?-dihydroxystilbenes represented by STR#I. Further, a novel sirtuin modulating composition comprising an orally bioavailable SIRT-1 enhancing compound 2,3?,5?,6-tetrahydroxy-trans-stilbene represented by STR#II is also disclosed.

Abstract: The present invention includes a transdermal composition which contains a pharmaceutically effective amount of a cannabinoid for delivery of the cannabinoid to the bloodstream of a user. The composition may comprise the following components: a surfactant-lecithin organogel; and a cannabinoid. The composition may also comprise an exogenous terpene. The cannabinoid is capable of diffusing from the composition into the bloodstream of the user, and may be used in methods for treating a patient suffering from a condition such as pain, nausea and emesis, convulsions, muscle spasm, inflammation, depression, and cachexia.

Abstract: Ophthalmic, otic and nasal compositions containing a new class of antibiotics (e.g., moxifloxacin) are disclosed. The compositions preferably also contain one or more anti-inflammatory agents. The compositions may be utilized to treat ophthalmic, otic and nasal conditions by topically applying the compositions to the affected tissues.

Abstract: The present invention relates to method(s) of treating a subject afflicted with cancer or a precancerous condition, an inflammatory disease or condition, and/or stroke or other ischemic disease or condition, the method comprising administering to the subject or patient in need a composition comprising a therapeutically effective amount of a substituted cis or trans-stilbene.

Abstract: A highly bioavailable, water soluble, sustained release nanoformulation comprising a hydrophobic plant derived compound(s) in an emulsifier phase, and aqueous phase. The formulation provides sustained release of the hydrophobic plant derived compound(s) over a 24 hr time period. A process for preparation of the water soluble nanoformulation is described.

Abstract: A method for preparing hydro/organo gelators from disaccharide sugars by biocatalysis and their use in enzyme-triggered drug delivery. Controlled delivery of an anti-inflammatory, chemopreventive drug is achieved by an enzyme-triggered drug release mechanism via degradation of encapsulated hydrogels. The hydro- and organo-gelators are synthesized in high yields from renewable resources by using a regioselective enzyme catalysis and a known chemopreventive and anti-inflammatory drug, curcumin, is encapsulated in the gel matrix and released by enzyme triggered delivery. The release of the drug occurs at the physiological temperature and control of the drug release rate is achieved by manipulating the enzyme concentration and temperature. The by-products formed after the gel degradation clearly demonstrated the site specificity of degradation of the gelator by enzyme catalysis.

Abstract: Provided are oral pharmaceutical compositions comprising sustained release or a combination of sustained and immediate release formulation of cannabinoids, a process for their preparation and methods of use thereof.

Abstract: Some embodiments of a system or method for applying a barrier composition to a targeted skin surface can be used to as a preventative measure to reduce the likelihood of transmission of microbial entities from an external source (e.g., a floor surface or another surface) to the targeted skin surface.

Abstract: A molecule mixture comprising an amphipathic molecule of type A, which has an overall positive charge in the hydrophilic region, an amphipathic molecule of type B and a polyphenol C, the method for producing the molecule mixture, and the use thereof. The molecules of types A and B are present at a molecular ratio of A:B of 1(±0.2):1(±0.2) mol/mol. A method for producing the mixture and the use is also disclosed.

Abstract: In certain embodiments the methods of preventing or delaying the onset of a pre-Alzheimer's condition and/or cognitive dysfunction, and/or ameliorating one or more symptoms of a pre-Alzheimer's cognitive dysfunction, and/or preventing or delaying the progression of a pre-Alzheimer's condition or cognitive dysfunction to Alzheimer's disease, and/or of promoting the processing of amyloid precursor protein (APP) by the non-amyloidogenic pathway are provided. In certain embodiments the methods involve administering, or causing to be administered, to a subject in need thereof certain formulations comprising or more active agent(s) selected from the group consisting of tropisetron disulfiram, honokiol, nimetazepam, and/or derivatives or analogs thereof.

Abstract: Hydroxytyrosol or olive juice containing hydroxytyrosol in combination with at least one of the compounds selected from the group consisting of: creatine, coenzyme Q10, resveratrol, caffeine, carnitine, B vitamins (B1, B2, B3, B5, B6, and/or B12) and ginseng (preferably: root) extract. can be used to maintain or increase mitochondrial biogenesis in cardiac muscle, skeletal muscles, and liver tissue.

Abstract: Methods of treating a head and neck cancer are disclosed.

Abstract: The present disclosure describes economical processes to improve the bioavailability of nutraceuticals by formulations that induce micronization and sustained release. The inventive process can be used to increase the solubility and bioavailability of lipophilic and moderately water-soluble nutraceuticals by combining excipients that increase the solubility and induce sustained release of the active compounds. The inventive process also can be used to increase the residence time of highly water-soluble nutraceuticals that are metabolized and eliminated quickly from the body, consequently increasing the therapeutic potential. The disclosed formulations advantageously are freely flowing powders that can be used to formulate with other ingredients into tablets, capsules, or the like; or used as bulk powders.

Abstract: The present disclosure describes economical processes to improve the bioavailability of nutraceuticals by formulations that induce micronization and sustained release. The inventive process can be used to increase the solubility and bioavailability of lipophilic and moderately water-soluble nutraceuticals by combining excipients that increase the solubility and induce sustained release of the active compounds. The inventive process also can be used to increase the residence time of highly water-soluble nutraceuticals that are metabolized and eliminated quickly from the body, consequently increasing the therapeutic potential. The disclosed formulations advantageously are freely flowing powders that can be used to formulate with other ingredients into tablets, capsules, or the like; or used as bulk powders.

Abstract: A composition to be administered to a mammal for treating hearing loss is disclosed herein. The composition consists essentially of a biologically effective amount of vitamin A, vitamin C, vitamin E, and a vasodilator comprising magnesium. The composition optionally includes a withanolide and/or resveratrol. The vitamin A, vitamin C, vitamin E, and the vasodilator comprising magnesium provides an additive effect that is equal to or greater than a sum of the effects of the individual components.

Abstract: Provided are cellulose esters useful for inhibiting solution crystallization of drugs. Specific polymers include cellulose esters of formula I: wherein n of the ?-carboxyalkanoyl group, is 3, 4, 6, or 8 to provide a ?-carboxyalkanoyl group chosen from succinoyl, glutaroyl, adipoyl, sebacyl, and suberyl groups; and wherein R is chosen from: a hydrogen atom; and an alkanoyl group chosen from acetyl, propionyl, butyryl, valeroyl, hexanoyl, nonanoyl, decanoyl, lauroyl, palmitoyl, and stearoyl groups; wherein there is a total degree of substitution of the alkanoyl group and the ?-carboxyalkanoyl group of at least 2.0; and wherein the polymer comprises m repeating units where n=1 to 1,000,000, or 10 to 100,000, or 100 to 1,000, such as 1 to 6,000. Embodiments further include compositions comprising cellulose esters and poorly water-soluble drugs, which compositions exhibit greater solubility and stability in solution as compared to the drugs alone.

Abstract: A method for reducing scarring comprises applying into a wound a composition comprising resveratrol. The wound was formed at most one day before the applying, and no part of the skin surface of the wound is more than 3 cm from uninjured skin.

Abstract: Disclosed are nanoparticle compositions comprising nanoparticles prepared from denatured, cross-linked albumin and a therapeutic agent for treating a neutrophil-mediated inflammation, and methods of treating neutrophil-mediated inflammation using the compositions.

Abstract: The invention relates to the use of cannabinoid-containing plant extracts in the prevention or treatment of neural degeneration. In particular, the invention relates to use of one or more cannabinoid-containing plant extracts in the prevention or treatment of neural degeneration, wherein the one or more cannabinoid-containing plant extracts comprise: i) a cannabinoid-containing fraction; and ii) a non-cannabinoid containing fraction.

Abstract: The present invention relates to cannabinoids for use in the treatment of neuropathic pain. Preferably the cannabinoids are one or more phytocannabinoids of: cannabigerol (CBG), cannabichromene (CBC), cannabidivarin (CBDV) or tetrahydrocannabivarin (THCV). More preferably the phytocannabinoids are isolated and/or purified from cannabis plant extracts.

Abstract: The present invention relates to a method of reducing the body weight of a subject by administering an effective amount of an estrogen receptor modulator (ERM), optionally, in combination with an anti-obesity or weight loss agent.